-
2022-501697-19-00
5
Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Lymphocytic Leuke
-
2022-502779-40-99
5
Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
-
2024-518237-28-00
6
recurrence of acute biliary pancreatitis
-
2024-518420-80-00
5
Primary infection prophylaxis for secondary immunodeficiency (SID) in
-
2025-521632-12-00
5
Patients on Factor Xa inhibitor treatment needing an urgent interventi
-
2025-522475-28-00
5
Pulmonary Hypertension (PH) with Heart Failure with preserved left ven
-
2025-522916-17-00
3
Urinary Tract Infections
-
2025-523010-89-00
3
Pulmonary arterial hypertension
-
2025-524289-56-00
6
Asthma
-
2024-514754-79-00
4
2026-05-06
Pulmonary Arterial Hypertension (PAH)
-
2025-522867-13-00
4
2026-04-27
Non Small Cell Lung Cancer
-
2024-511983-97-00
4
2025-09-29
Adult patients with indolent MCL who have not previously received trea
-
2023-508441-41-00
6
2024-07-08
Bacteriemia producida por P. aeruginosa.
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2022-503070-36-00
5
2025-12-23
Group B streptococcus (GBS) disease
-
2024-517131-52-00
5
2025-11-03
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lym
-
2024-513613-12-00
9
2025-09-18
Part A: Healthy volunteers (Part A is not applicable to the EU; for in
-
2024-520276-10-00
5
2025-09-04
Non-constipated Irritable Bowel Syndrome (IBS)
-
2024-514440-86-00
4
2025-08-04
Relapse/Refractory Large B Cell Lymphoma
-
2023-510294-34-00
5
2025-06-12
small lymphocytic lymphoma (SLL)
-
2024-515162-13-00
5
2025-04-29
Eosinophilic Asthma
-
2023-510323-30-00
5
2025-01-24
First-line treatment of recurrent or metastatic PD-L1+ head and neck s
-
2024-513004-33-00
4
2025-01-14
Hepatotoxicity
-
2024-515381-14-00
6
2024-11-20
heartburn and or reflux